Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation inflammation, and activated mononuclear phagocytes

摘要

Intravenous immunoglobulin (IVIG) is administered in a variety of clinical settings, with wide use in the treatment of primary and secondary immunoglobulin deficiencies,1 as well as in autoimmune or inflammatory conditions believed to be mediated by autoantibodies or T cells.2-3 When used as an immuno-modulatory agent, IVIG is administered in higher doses typically at 2 g/kg.4 High doses of IVIG were first administered for the treatment of pediatric immune throm-bocytopenia (ITP).5 Mechanisms of action remain incompletely defined, although interference of phagocyte Fc receptor-mediated immune clearance is thought to play a prominent role.